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Abstract MicroRNAs (miRNAs) are a class of noncoding
RNAs and function as key regulators of gene expression at
the post-transcriptional level. In this study, we found that miR-
495 reduces cell growth, induces apoptosis and suppresses the
migration of endometrial cancer by directly inhibiting FOXC1
expression. Further analysis revealed that FOXC1 promotes
growth and migration and functions as an oncogene in vitro.
FOXC1 overexpression reversed the cellular responses medi-
ated by miR-495 in endometrial cancer cells. We also found
that miR-495 suppresses the growth of endometrial cancer
in vivo. Altogether, these results indicate that miR-495 acts
as a tumour suppressor gene by targeting FOXC1 at the post-
transcriptional level in endometrial cancer.
Keywords Endometrial cancer . MicroRNA . FOXC1 .
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Introduction
MicroRNAs (miRNAs) are a group of highly conserved small
noncoding RNAs and regulate target expression by complete
or incomplete complementarity with messenger RNA of the
target gene 3′UTR at the seed sequence to lead to either
mRNA degradation or repression of translation [1].
Documented evidence has shown that miRNAs are involved
in many cellular processes, including development, apoptosis,
differentiation, metabolism and stress response, depending
upon the regulation of specific target genes [1]. Meanwhile,
miRNAs participate in the development of multiple diseases,
including tumourigenesis [2]. The involvement of miRNAs in
malignant tumours has been elucidated in multiple studies.
Some miRNAs promote the process of tumourigenesis and
function as oncogenes. For example, miR-106b is associated
with a greater capacity for cell proliferation by the inhibition
of G1-phase cell cycle arrest in melanoma cells [3]. In oesoph-
ageal squamous cell carcinoma, miR-9 promotes tumour me-
tastasis by downregulating the expression of E-cadherin [4].
However, other miRNAs are expressed at a low level and act
as tumour suppressors. MiR-27a can directly target KRAS to
inhibit cell proliferation in oesophageal squamous cell carci-
noma [5]. miR-99a suppresses the metastasis of human non-
small cell lung cancer cells by targeting the AKT1 signalling
pathway [6]. Recent studies have indicated that miRNAs are
tissue- and disease-specific [7], which function and are
expressed differently in many types of cancers. Thus,
miRNAs can serve as powerful biomarkers, which are useful
in the diagnosis and therapy of cancer [8].
In the tumour-associated miRNAs, the mechanism of miR-
495 in cancer initiation and progression drew our attention,
because miR-495 has been found to perform various biologi-
cal functions in a variety of types of cancer. For instance, in
breast cancer stem cells, miR-495, upregulated by E12/E47,
promotes oncogenesis and hypoxia resistance via the down-
regulation of E-cadherin and REDD1 [9]. Li et al. found that
miR-495 acts as a tumour suppressor and inhibits gastric can-
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of the PTP family, PRL-3 [10, 11]. However, until now, the
function and molecular mechanism of miR-495 in endometri-
al cancer remain largely unknown.
Endometrial cancer, the most prevalent cancer of the fe-
male genital tract, is the third most frequent gynaecologic
malignancy worldwide. Approximately 42,160 cases were di-
agnosed with endometrial cancer, and 7780 women died of it
in the USA in 2009 [12]. Worldwide, 226,000 women were
diagnosed with endometrial cancer [13]. Previous studies
have reported that endometrial cancer is a multifactorial dis-
ease with several aberrant steps in gene expression [14].
Several studies have indicated the alteration of miRNA ex-
pression in endometrial cancer, such as miR-101 [15], miR-
205 [16], miR-204 [17] and miR-34a [18], miR-194 [19] and
miR-130b [20], which are confirmed to be associated with the
malignant phenotypes of endometrial cancer. In this study, we
aimed to identify the novel biological function of miR-495
suggested by miRNA target prediction databases in endome-
trial cancer.
FOXC1 is a member of the forkhead box (FOX) transcrip-
tion factor family and participates in a multitude of biological
processes. Dysregulation of the FOXC1 protein contributes to
carcinogenesis, including proliferation, apoptosis, differentia-
tion, invasion and metastasis of several human cancers [21].
Muggerud et al. reported that FOXC1 knockdown mediates
cell proliferation, migration and invasion inhibition in breast
cancer cells [22]. In response to TGF-β, FOXC1 is upregulat-
ed transcriptionally and suppresses cell growth [23]. FOXC1
knockdown by siFOXC1 reduces the migration and invasion
of HEC1A cells in endometrial cancer cells [17]. Here, we
found that miR-495 was frequently downregulated, and
FOXC1 was overexpressed in endometrial cancer tissues rel-
ative to normal tissues. miR-495 suppresses the growth of
endometrial cancer cells by inducing cell apoptosis. miR-
495 can also suppress the migration of endometrial cancer
cells. Furthermore, FOXC1 was identified as a direct target
of miR-495. Knockdown of FOXC1 suppressed, and overex-
pression of FOXC1 promoted the cell growth andmigration of
endometrial cancer in vitro. In vivo, we also examined the
negative relationship between miR-495 and FOXC1 and the
opposite effects of tumour growth. Taken together, our study
is the first to document that miR-495 acts as a tumour sup-




The endometrial carcinoma cell lines AN3CA and KLE were
obtained from ATCC and maintained in DMEM/F12 supple-
mented with 10% FBS, 100 units/ml penicillin and 100 μg/ml
streptomycin. The cells were incubated at 37 °C in a humid-
ified chamber supplemented with 5 % CO2.
Human tissue samples
Ten human endometrial cancer tissues and five normal tissues
were obtained from the Tumor Bank Facility of Tianjin
Medical University Cancer Institute and the National
Foundation of Cancer Research (TBF of TMUCIH and
NFCR) with the patients’ informed consent. All tissue stages
of cancer were confirmed by pathology and immunohisto-
chemistry, and samples were collected and frozen in liquid
nitrogen and stored at 80 °C. The diagnoses of these samples
were verified by pathologists. Approval for this work was
granted by the Ethics Committee of Tianjin Medical
University.
RNA isolation and quantitative real-time (qRT)-PCR
assay
Large and small RNAs from the tissue were isolated with
mirVana miRNA Isolation Kit (Ambion, Austin, TX, USA)
according to the manufacturer’s protocol. For RNA integrity
assessment, part of an RNA sample was used for concentra-
tion and purity measurement (by A260 and A280 spectropho-
tometry), and another part of the sample was run on a 1.5 %
denaturing agarose gel stained with ethidium bromide. A ratio
of the absorbance at 260 and 280 nm (A260/280) of 1.8–2 was
accepted. The sharp, clear 28S and 18S rRNA bands and the
2:1 ratio (28S:18S) were good indicators that the RNA was
completely intact.
Five micrograms of an RNA sample was reverse-
transcribed to cDNA using oligo (dT) primers and M-MLV
reverse transcriptase (Promega, Madison WI); the cDNAwas
used for the amplification of FOXC1 and β-actin.
Quantitative real-time PCR (qRT-PCR) was performed to de-
tect the relative transcript levels of miR-495 and FOXC1.
PCR was performed under the following conditions: 94 °C
for 4 min was followed by 40 cycles of 94 °C for 1 min,
56 °C for 1 min and 72 °C for 1 min.
To detect the mature miR-495 levels, a stem-loop RT-PCR
assay was performed using specific RT and PCR primers. U6
snRNAwas used as an endogenous control. Five micrograms
of total RNAwas reverse-transcribed to cDNAwith a specific
RT primer that could fold into a stem-loop structure. The PCR
cycles were as follows: 94 °C for 4 min was followed by
40 cycles of 94 °C for 30 s, 50 °C for 30 s and 72 °C for
30 s. PCR was performed using SYBR Premix Ex Taq Kit
(TaKaRa, Madison, WI) according to the manufacturer’s in-
structions and analysed using 7300 RT-PCR system (ABI).
The relative expression levels of the gene of interest were
calculated by the 2−ΔΔCt method. All primers were synthe-
sised by AuGCT Inc. (Beijing, China).
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Cell transfection
One day before transfection, the cells were plated in a 48-well
or 24-well plate. The transfections were performed using
Lipofectamine 2000 Reagent according to the manufacturer’s
protocol (Invitrogen, Carlsbad, CA, USA). The plasmids were
used at a final concentration of 5 ng/l. To determine the trans-
fection efficiency, we transfected either pcDNA3.1-EGFP or
the negative control, pcDNA3.1, into the two cell lines and
assessed the level of enhanced green fluorescent protein
(EGFP) expression 48 h after transfection using fluorescence
microscopy.
Plasmid construction
The pSilencer/shRNA- FOCX1 (siFOCX1) vector was ob-
tained by annealing two single-stranded complementary se-
quences that contained BamHI and HindIII restriction sites
at the ends. The fragment was then cloned into the
pSilencer2.1/neo vector (Ambion) between the BamHI and
HindIII sites.
The pcDNA3.1 vector was used to generate a FOCX1-
overexpression plasmid. The full-length human FOCX1
cDNA sequence (GenBank TM, NM_001453.2) was ampli-
fied by PCR using cDNA isolated from foetal brain tissue as
the template. The FOCX1 gene was inserted into the EcoRI
and XbaI restriction sites.
The EGFP expression vector (pcDNA3.1/EGFP) was con-
structed as previously described. The 3′UTR fragment of the
FOCX1 gene containing the predicted miR-495 binding site
was amplified by PCR using the primers. The PCR products
were cloned into the pcDNA3.1/EGFP plasmid between the
BamHI and EcoRI restriction sites, and the resulting vector
was named pcDNA3.1/EGFP- FOCX1 3′UTR. All of the
inserted DNAs mentioned above were verified by DNA
sequencing.
Target prediction
TargetScan, PicTar and miRBase were used to predict the
putative targets of miR-495.
EGFP reporter assay
The 3′UTR segments of FOCX1 containing putative binding
sites for miR-495 were inserted into pcDNA3.1/EGFP
(pcDNA3.1/EGFP- FOCX1-UTR 648, 607 and 1629). The
endometrial cancer cells AN3CA and KLEwere cotransfected
with pcDNA3.1/pri-miR-495 and pcDNA3.1/EGFP-
FOCX1-UTR or with pcDNA3.1 negative control vector in
48-well plates. The vector pDsRed2-N1 (Clontech, USA) ex-
pressing red fluorescent protein (RFP) was used for normal-
isation. Approximately 48 h after transfection, the
fluorescence intensity was measured with an F-4500 fluores-
cence spectrophotometer (Hitachi, Tokyo, Japan). The EGFP
expression was normalised to RFP expression for each sam-
ple. Each experiment was repeated at least three times.
Western blot
The transfected cells were washed with phosphate buffered
saline (PBS) and lysed with radioimmunoprecipitation assay
buffer (150 mM NaCl, 1 % Nonidet P-40, 1 % Triton X-100,
1 mM MgCl2, 0.1 % SDS, 10 Mm Tris-HCl, pH 7.4) for
30 min at 48 h after transfection. Cell extracts were cleared
by centrifugation at 12,000×g for 10 min at 4 °C, and the
supernatant was used for western blot analyses. All proteins
were resolved on a 10 % SDS denaturing polyacrylamide gel
and then transferred onto a nitrocellulose membrane.
Membranes were incubated with blocking buffer for 90 min
at room temperature and were then incubated overnight at
4 °C with a rabbit polyclonal anti-FOCX1 antibody (1:200;
Tianjin Saier Biotech, Tianjin, China) or anti-glyceraldehyde
phosphate dehydrogenase (GAPDH) antibody (1:200; Tianjin
Saier Biotech, Tianjin, China) prepared in blocking buffer.
The membranes were washed and incubated with a horserad-
ish peroxidase (HRP)-conjugated secondary antibody
(1:1000; Tianjin Saier Biotech, Tianjin, China). Protein ex-
pression was assessed by enhanced chemiluminescence and
exposure to chemiluminescent film. LabWorks Image
Acquisition and Analysis Software (UVP) was used to quan-
titate band intensities.
Cell viability assay
Twenty-four hours after transfection, cells were seeded in 96-
well plates at either 6*103 cells/well (AN3CA cells) or
15*103 cells/well (KLE cells). The MTT assay was used to
measure cell viability at 24, 48 and 72 h after being seeded.
The cells were incubated withMTT (at a final concentration of
0.5 mg/ml) at 37 °C for another 4 h. Then, the medium was
removed, and the precipitated formazan was dissolved in
100 μl of dimethyl sulfoxide (DMSO). After shaking for
15 min, the absorbance at 570 nm (A570) was detected using
a μQuant universal microplate spectrophotometer (BioTek
Instruments, Winooski, VT).
Colony formation assay
Cells were counted and seeded (300 cells/well) in 12-well
plates (in triplicate). Fresh culture mediumwas replaced every
three days. Colonies were counted only if they contained more
than 50 cells, and the number of colonies was counted either
12 days (AN3CA cells) or 15 days (KLE cells) after seeding.
The cells were stained using crystal violet. Colony formation
was calculated by the colony formation number.
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Flow cytometry analysis of cell apoptosis
To measure apoptosis, cells were collected, washed with PBS
and stained with fluorescein isothiocyanate-labelled annexin
V (Invitrogen) and propidium iodide, and this was followed
by flow cytometry analysis [24].
In vitro migration assays
In vitro cell migration assays were performed using transwell
chambers (pore size of 8 uM; Costar, Corning, NY).
Transfected cells were resuspended in serum-free medium,
and 200 μl of the cell suspension (4*104 cells) was added to
the upper chamber. Complete medium was added to the bot-
tom wells of the chambers. For the screen, the cells that had
not migrated after either 7 h (AN3CA cells) or 18 h (KLE
cells) were removed from the upper face of the filters using
cotton swabs. After fixation and staining in a dye solution
containing 0.1 % crystal violet and 20 % methanol, the cells
that had adhered to the lower membrane of the inserts were
counted. Images of three different fields (5*magnification)
were taken for each membrane, and the number of migratory
cells was counted. The mean of triplicate assays for each ex-
perimental condition was used.
Murine xenograft model
Six-week-old female nude mice were purchased from the an-
imal facilities of the Chinese Academy of Medical Sciences
and were housed in the animal facilities of Tianjin Medical
University as approved by the Institutional Animal Care and
Use Committee. AN3CA cells and KLE cells were subcuta-
neously injected into the flanks of the nude mice. After
22 days, the mouse were sacrificed, and the tumours were
harvested and then stored at −80 °C for subsequent analysis.
Immunohistochemistry
Immunohistochemistry was performed according to previous-
ly described methods [25]. The sections were pre-treated
using microwave irradiation and were then blocked and incu-
bated with polyclonal rabbit anti-human FOXC1 antibodies
(Saier Biotechnology). The staining intensity was then
assessed.
Statistical analysis
Data are expressed as the means±SD. Statistical analyses
were performed using a paired t test. A p value <0.05 was
considered to be statistically significant. One representative
experiment is shown in the duplicates or triplicates used for
the statistical analysis.
Results
miR-495 suppresses cell growth and induces apoptosis
in endometrial cancer
In order to investigate the effects of miR-495 in endometrial
cancer, a miR-495 overexpression vector, pcDNA3.1/pri-
miR-495 (miR-495), was constructed. Two endometrial can-
cer cell lines, AN3CA and KLE, were applied to examine the
effects of miR-495 on cell viability, colony formation and
apoptosis. The MTT assay was used to evaluate cell viability.
As shown in Fig. 1a, the overexpression of miR-495 reduced
the viability both in AN3CA and KLE cells at 24, 48 and 72 h
post-transfection. To further determine the effect of miR-495
on long-term and independent cellular growth ability of
AN3CA cells, we preformed the colony formation assay.
The colony numbers in AN3CA cells transfected with miR-
495 decreased by approximately 75.8 % (Fig. 1b). In KLE
cells, the colony numbers were reduced by 75.3 % (Fig. 1b).
To further explore the mechanism of miR-495 in reducing cell
growth, we measured cell apoptosis of miR-495 in AN3CA
and KLE cells. Flow cytometry (FCM) was used to examine
the properties of cell apoptosis. As shown in Fig. 1c, the group
of miR-495 overexpression had a higher property of apoptosis
compared with the negative control in AN3CA and KLE cells.
Meanwhile, we also detected the marker of cell apoptosis,
active caspase 3 and pro-caspase 3. The results shown that
both in AN3CA and KLE cells, caspase 3 activity was much
higher in miR-495 group (Fig. 1c). These results indicated that
cell growth inhibition by miR-495 is generated as a conse-
quence of the promotion of cell apoptosis in vitro.
miR-495 suppresses the properties of migration in vitro
Migration is one of the essential factors for metastasis, which
is a dangerous property of cancer. To investigate the effect of
miR-495 on the migration of endometrial cancer, a transwell
assay without Matrigel was employed. In AN3CA cells, ap-
proximately 30 % of cells overexpressing miR-495 migrated
to the basal side of the membrane compared to the negative
control (Fig. 1d). Similarly, 34.6 % of KLE cells with miR-
495 overexpression migrated to the basal side relative to the
control cells (Fig. 1d). These data suggested that miR-495
inhibits cell migration in vitro and partly indicates the effect
of miR-495 on the malignant phenotype of endometrial
cancer.
miR-495 downregulates FOXC1 expression by binding
the 3′ UTR of FOXC1 in endometrial cancer
The inhibition of cell growth and migration by miR-495 is
derived from its target gene. To explore the mechanisms of
miR-495 regulation in endometrial cancer, we searched for the
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potential targets of miR-495 using three bioinformatic algo-
rithms: TargetScan, PicTar and miRanda. Using these pro-
grams, we selected FOXC1 as a miR-495 target gene for fur-
ther study due to the malignancy phenotype in other types of
cancer, which might be consistent with the phenotype of miR-
495 in endometrial cancer. To elucidate whether miR-495 di-
rectly regulates FOXC1, an enhanced green fluorescent pro-
tein (EGFP) reporter assay was used to validate the target sites
in the FOXC1 3′UTR. There are three predicted miR-495
binding sites (648, 667 and 1629) in the 3′UTR of FOXC1
mRNA (Fig. 2a). The binding sites for miR-495 on the
FOXC1 3′UTR are conserved amongst species. First, we
constructed an EGFP reporter plasmid by inserting the miR-
495 binding sites (648, 667 and 1629) of FOXC1 3′UTR
downstream of the EGFP stop codon (pcDNA3/EGFP-
FOXC1-3′UTR 648, 667 and 1629). Next, AN3CA and
KLE cells were cotransfected with the FOXC1-3′UTR report-
er plasmid (UTR (648), UTR (667) and UTR (1629)) and
pcDNA3.1/pri-miR-495 (miR-495) plasmids or a control vec-
tor. The fluorescent intensity was measured 48 h after trans-
fection. As shown in Fig. 2b, the normalised intensity of fluo-
rescence was significantly reduced in the pcDNA3.1/pri-miR-
495 plasmid-transfected group in the sites of UTR (667) and
UTR (1629) compared to the negative control. However, there
Fig. 1 The functions of miR-495
in endometrial cancer cells,
AN3CA and KLE cells. a The
cell viability of AN3CA and KLE
cells was determined by MTT
assay 24, 48 and 72 h after
transfection (n=3,*p<0.05). b
Colony formation assay was
employed to detect the effect of
miR-495 on the cell growth
activity of AN3CA and KLE cells
(n=3,*p<0.05). c Flow
cytometry analysis and western
blot were used to detect cell
apoptosis and caspase 3 in
AN3CA and KLE cells
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was no significant difference in the normalised intensity of
fluorescence cotransfected with FOXC1-3′UTR (648) and
pcDNA3.1/pri-miR-495. These results suggested that miR-
495 binds directly to sites 667 and 1629 of FOXC1-3′UTR.
In addition, to verify that miR-495 could downregulate the
endogenous expression of FOXC1 at the post-transcriptional
level, qRT-PCR and western blot analyses were performed to
detect the effect of miR-495 on FOXC1 mRNA and protein
expression. AN3CA and KLE cells were transfected with
pcDNA3.1/pri-miR-495 (miR-495) and the negative control.
As shown in Fig. 2c, the overexpression of miR-495 led to an
approximate 75.5 % and 72 % reduction in FOXC1 mRNA
expression in AN3CA and KLE cells, respectively.
Additionally, the FOXC1 protein level was reduced by
65.5 % compared with the control group in AN3CA and
KLE cells (Fig. 2d). These results suggested that miR-495
negatively regulates endogenous FOXC1 expression.
Furthermore, real-time PCR was also performed in five endo-
metrial cancer cell lines, and the opposite trend was observed
in the miR-495 and FOXC1 mRNA expression, which is
Fig. 2 FOXC1 is directly
repressed by miR-495. a The
FOXC1 3′UTR has three putative
miR-495 binding sites (648, 667
and 1269). b The intensity of
EGFP fluorescence in reporter
cells transfected with miR-495
was measured after 48 h of
transfection. c The expression
levels of FOXC1 in AN3CA and
KLE cells were significantly
altered following transfection
with miR-495 by qRT-PCR using
U6 snRNA for normalisation. d
The protein levels of FOXC1 in
AN3CA and KLE cells decreased
when miR-495 was
overexpressed. e, f The
expression level of miR-495 and
FOXC1 in five endometrial
cancer cells (*p<0.05)
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consistent with the regulation between them (Fig. 2e, f). In
combination, miR-495 directly binds the 3′UTR of FOXC1
and suppresses its expression in vitro.
FOXC1 promotes cell growth and migration
and suppresses apoptosis in vitro
Considering that miR-495 directly regulates the expression of
FOXC1 and suppresses cell growth and migration in vitro, we
next examined the function of FOXC1 in endometrial cancer.
An siRNA expression vector (siFOXC1) was constructed suc-
cessful (Fig. 3a) and transfected into AN3CA and KLE cells
to test cell viability, colony formation, apoptosis and migra-
tion. As expected, siFOXC1 caused a significant reduction of
cell viability in AN3CA cells using the MTT assay (Fig. 3b).
Similarly, the inhibition of FOXC1 reduced cell viability in
KLE cells (Fig. 3b).Meanwhile, a colony formation assay was
performed to determine the long-term effect on cell growth.
The formation of colonies in the group of FOXC1 siRNAwas
reduced approximately 77.16 % and 72.97 % in AN3CA and
KLE cells (Fig. 3e). Next, we performed FCM to examine the
properties of cell apoptosis. As shown in Fig. 3d, cells
transfected with FOXC1 siRNA had a higher rate of cell ap-
optosis compared with the negative control both in AN3CA
cells and KLE cells, which indicated that the contribution to
cell growth by FOXC1 was due to the inhibition of apoptosis.
Furthermore, we also performed a transwell migration assay
to determine the effect of FOXC1 on cell migration in endo-
metrial cancer. Knockdown of FOXC1 expression resulted in
a significant decrease in the rate of cell migration in AN3CA
(78.45 %) and KLE (75.93 %) cells compared with the nega-
tive control (Fig. 3c). These results demonstrated that the pro-
motion effect on cell growth and migration by FOXC1 is
consistent with the effect of miR-495 in endometrial cancer.
Ectopic expression of FOXC1 counteracts the effects
of miR-495 in endometrial cancer cells
The previous results confirmed that the overexpression of
miR-495 induced the inhibition of cell growth and migration
required by downregulation of FOXC1. To further confirm
that the effects of miR-495 on the growth and migration of
AN3CA and KLE cells are mediated by FOXC1, a rescue
experiment was performed. The overexpression vector of
FOXC1, which contains the FOXC1 ORF without the 3′
UTR, was constructed to avoid the influence of miRNAs. If
the effect of miR-495 is specific, co-expression of FOXC1
should be able to reverse the phenotype of miR-495 overex-
pression. The AN3CA and KLE cells were cotransfected with
pcDNA3.1/miR-495 plus pcDNA3.1/FOXC1 or pcDNA3.1/
miR-495 plus empty pcDNA3.1. In the colony formation as-
say, ectopic FOXC1 expression counteracted the inhibition of
cell growth and migration caused by miR-495 compared with
the control vector (Fig. 4a). As shown in Fig. 4b, the FCM
assay indicated that the overexpression of FOXC1 reversed
the promotion of miR-495 on apoptosis on AN3CA and KLE
cells. In addition, migration caused by miR-495 was abrogat-
ed in cells cotransfected with the FOXC1 ectopic vector
(Fig. 4c). Therefore, these results provide further evidence that
FOXC1 functions as a target of miR-495 and is involved in the
miR-495-mediated malignancy phenotype of endometrial
cancer.
miR-495 suppressed tumour growth in vivo
To examine the effect of miR-495 on the growth of tumours
in vivo, we screened AN3CA-pooled clones and KLE-pooled
clones with G418 to gain the stable expression of miR-495
(AN3CA/miR-495, KLE/miR-495) and the negative control
(AN3CA/pcDNA3.1 and KLE/pcDNA3.1). AN3CA/miR-495-
or AN3CA/pcDNA3-pooled cloneswere injected subcutaneous-
ly into the flanks of nude mice. The volume of the nodules was
measured every three days starting from the seventh to the 22nd
day to examine the effect of miR-495 on tumour growth.
Compared with the control group, the volume of nodules was
smaller in the AN3CA/miR-495 group than in the AN3CA/
pcDNA3.1 group (Fig. 5a). The KLE-pooled clones obtained
the same results (Fig. 5a). After 22 days, the nodules were har-
vested and divided for qRT-PCR and western blot analyses. The
volume of nodules was smaller in the miR-495 both in AN3CA-
and KLE-pooled clones (Fig. 5b). qRT-PCR was used to exam-
ine the expression ofmiR-495 in the pooled clones. As expected,
themiR-495 expressionwas increased (75.25% and 73.40%) in
the nodules of miR-495 overexpression derived from AN3CA-
and KLE-pooled clones (Fig. 5c), respectively. To further deter-
mine the relationship between miR-495 and FOXC1 in vivo, we
performed western blotting to examine FOXC1 expression. The
results demonstrated that the expression levels of FOXC1 in the
AN3CA/miR-495 and KLE/miR-495 groups were reduced by
approximately 70.5% and 62.50%, respectively, comparedwith
the negative control (Fig. 5c), which were consistent with the
results from endometrial cancer cells in vitro. Together, these
results indicated that miR-495 suppresses the endometrial cancer
growth and downregulates the expression of FOXC1 in vivo.
Expression of miR-495 and FOXC1 in endometrial cancer
tissues and cells
To evaluate the potential role of miR-495 and FOXC1 in en-
dometrial cancer, ten tissues from endometrial cancer patients
and five endometrial tissues from healthy people were applied
to detect the expression level of miR-495 and FOXC1 using
qRT-PCR, western blot and immunohistochemical staining.
We found that miR-495 expression decreased progressively
both in endometrial cancer patients’ tissues and healthy peo-
ple’s endometrial tissues compared with miR-495 expression
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from one normal tissue (Fig. 6a). However, miR-495 ex-
pression from endometrial cancer patients’ tissues de-
creased to a greater extent. Consistently, western blot assay
indicated that the expression of FOXC1 in endometrial
cancer patients’ tissues was much higher compared with
the normal tissues (Fig. 6b). To further confirm the reduced
levels of FOXC1 expression in endometrial cancer tissues,
we utilized immunohistochemical staining to detect the
FOXC1 protein levels. Compared with those of the normal
tissues, the FOXC1 protein levels were markedly increased
in the endometrial cancer patients’ tissues (Fig. 6c).
Overall, these results confirmed the relationship between
miR-495 and FOXC1 and their functions in endometrial
cancer tissues.
Fig. 3 FOXC1 affects viability,
colony formation apoptosis and
migration in AN3CA and KLE
cells. aWestern blot was used the
detect the expression of FOXC1
when FOXC1 was knocked
down. b The cell viability of
AN3CA and KLE cells was
determined by MTT assay 24, 48
and 72 h after transfection (n=
3,*p<0.05). c Transwell assay
was employed to detect the effect
of FOXC1 knockdown on the cell
migration of AN3CA and KLE
cells (n=3,*p<0.05). d Flow
cytometry analysis was used to
detect cell apoptosis in AN3CA
and KLE cells. e Colony
formation assay was employed to
detect the effect of FOXC1
knockdown on the cell growth
activity of AN3CA and KLE cells
(n=3,*p<0.05)
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Discussion
Endometrial cancer is the most widespread gynaecologic can-
cer amongst women. According to the clinical, molecular and
pathological data, endometrial cancer can be classified into
two subgroups [12]. The endometrioid type (Type I tumours),
which exhibits an altered PI3K/PTEN/AKT/mTOR signal
pathway, is oestrogen-dependent and well-differentiated with
a relatively favourable prognosis [26, 27]. The non-
endometrioid type (Type II tumours) exhibits p53 mutations
[28] and epidermal growth factor receptor 2 (HER-2) [29], is
oestrogen-independent and has a serous prognosis [30]. In
concert, aberrant molecular expression, including both onco-
genes and tumour suppressors, has been linked to
tumourigenesis and the progression of endometrial
malignancies [31]. From a mechanistic perspective, several
regulators of gene expression have been identified, in which
miRNAs play a critical role. miRNAs have been described as
oncogenes or tumour suppressors by regulating gene expres-
sion at the post-transcription level. Our study demonstrated
the function of a tumour-related miRNA, miR-495, in regula-
tion of endometrial cancer.
We provide several levels of evidence to identify miR-495
functions in regulation of endometrial cancer phenotypes. We
used theMTTassay to determine the effect of miR-495 on cell
viability in the AN3CA and KLE endometrial cancer cell
lines. When miR-495 was overexpressed, the viability of en-
dometrial cancer was reduced. In the colony formation assay,
we observed that the colony formation activity of AN3CA and
KLE cells transfected with pri-miR-495 was significantly
Fig. 4 FOXC1 rescues miR-495-
induced cellular phenotypes in
endometrial cancer. a A colony
formation assay was performed
after transfection. b Flow
cytometry analysis was used to
detect cell apoptosis in AN3CA
and KLE cells. c The ectopic
expression of FOXC1without a 3′
UTR rescued AN3CA and KLE
cell migration (*p<0.05)
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inhibited. To further explore the mechanism of the viability
and inhibition of colony formation by miR-495, we examined
cell apoptosis and the corresponding molecular marker. The
results showed that miR-495 could induce the apoptosis of
AN3CA and KLE cells. Furthermore, the migration activity
of AN3CA and KLE cells transfected with miR-495 was sig-
nificantly decreased. In parallel, the animal study showed that
miR-495 could repress the growth of nodules. These results
highlight the significance that miR-495, acting as a tumour
suppressor, alleviated the malignancy of endometrial cancer
both in vivo and in vitro.
As is commonly known, miRNAs possess different roles
by regulating target gene expression [32]. The identification of
specific miRNA target genes is critical for understanding the
mechanism involved in miRNA-related carcinogenesis.
Increasing evidence has shown that miRNAs regulate their
target genes by binding to the mRNA 3′UTR [33]. To identify
the target gene responsible for the effects of miR-495 on en-
dometrial cancer, we used bioinformatics and functional
knowledge to predict the miR-495 target gene and chose
FOXC1 as a candidate. The EGFP reporter system was used
to confirm themiR-495 binding sites in FOXC1 3′UTR. Three
sites exist in the FOXC1 3′UTR, and two of them are respon-
sive to miR-495 overexpression. The EGFP fluorescence in-
tensity of FOXC1 3′UTRwas specifically reduced in the miR-
495 overexpression group. These results suggested that miR-
495 regulates FOXC1 expression by directly binding to the
FOXC1 3′UTR. In parallel, endogenous FOXC1 mRNA and
protein expression decreased both in AN3CA and KLE cells
transfected with pri-miR-495. In addition, the inverse correla-
tion between miR-495 and FOXC1 mRNA in endometrial
cancer cells and tissues further supported this conclusion.
Fig. 5 miR-495 suppresses the growth of endometrial cancer through the
downregulation of FOXC1 in vivo. a The average volume of the tumour
nodules derived from AN3CA and KLE cells that were stably expressed
miR-495 in SCID mice. b The nodules obtained from the cancer cells
injected subcutaneously into the flanks of nude mice. c, d qRT-PCR and
western blot assay were performed to evaluate the expression levels of
miR-495 (c) and FOXC1 (d) in the tumour nodules (*p<0.05)
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Moreover, the expression of FOXC1 was reduced in the nod-
ules, which had a high level of miR-495 in vivo. Taken to-
gether, these results confirm the direct regulation of miR-495
on its target FOXC1.
The FOX gene family belongs to transcription factors and is
involved in many aspects of physiology and pathology [34].
FOXC1, which contains a characteristic DNA-binding
forkhead domain (FHD), is a member of the FOX gene family
[35]. Thus, FOXC1 also participated in the development of
cancer by regulating the target genes. FOXC1 interacts with
the Bmp-responsive enhancer to reduce Msx2 expression and
contribute to skull vault growth in breast cancer [36]. MMP7
has a downstream effect on FOXC1-mediated invasiveness
[37]. Meanwhile, increasing numbers of studies have shown
that some genes could directly regulate FOXC1 expression. In
breast cancer, EGFR activation induced FOXC1 transcription
and FOXC1 knockdown impaired cell proliferation andmigra-
tion [38]. FOXC1 is downregulated by miR-204 and reduces
cell migration in endometrial cancer [17]. Our results reveal the
link between miR-495 and the oncogenic factor FOXC1, be-
cause FOXC1 was confirmed to be a direct and functional
target gene of miR-495 in endometrial cancer. Thereafter, we
aimed to study whether the function of FOXC1 was consistent
with this regulation. The effect of FOXC1 on the processes of
endometrial cancer was validated by FOXC1 gain and loss of
function followed by cell viability, colony formation, apoptosis
and migration assays. In AN3CA and KLE cells, FOXC1 pro-
moted cell viability and colony formation by reducing cell
apoptosis. Previous studies showed that FOXC1 regulates the
epithelial-mesenchymal transition (EMT) and contributes to
cell migration [39, 40]. In this study, we also obtained the
promotion of migration by FOXC1, which is consistent with
this study. Importantly, the overexpression of FOXC1 can re-
verse the cell functions induced by miR-495 overexpression,
indicating that miR-495 reduced the malignancy of endometri-
al cancer, at least partially, by regulating FOXC1.
In summary, miR-495 functions as a tumour suppressor
gene and exhibits its biological role by regulating the expres-
sion of FOXC1 in endometrial cancer. Our study demonstrat-
ed a novel regulatory mechanism by which miR-495 inhibits
endometrial cancer cell growth by inducing apoptosis and
migration in vitro. Additionally, FOXC1 acts as an oncogene
in endometrial cancer. Animal studies also confirmed the neg-
ative regulation of FOXC1 by miR-495 in vivo. This study
helps us to further understand the miRNA-mediated regula-
tion mechanism in endometrial cancer and may provide an
important molecular diagnosis and treatment strategy for pa-
tients with endometrial cancer.
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